{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:55:59Z","timestamp":1791190559392,"version":"4.1.0"},"reference-count":105,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang\/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues. Mol Cancer Ther; 11(3); 526\u201337. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-11-0806","type":"journal-article","created":{"date-parts":[[2012,2,18]],"date-time":"2012-02-18T04:51:41Z","timestamp":1329540701000},"page":"526-537","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF\/mTOR Signaling Paradigm"],"prefix":"10.1158","volume":"11","author":[{"given":"Sumanta Kumar","family":"Pal","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Williams","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Josephson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Carmichael","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; 2Associated Urologists of Orange County, Santa Ana; 3Tower Urology; 4Division of Cancer Medicine, Developmental Therapeutics Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California; and 5Developmental Therapeutics, GU Committee, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,3,6]]},"reference":[{"key":"2022060800081626200_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib3","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060800081626200_bib5","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib6","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060800081626200_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2022060800081626200_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4503","article-title":"Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial","volume":"29","author":"Rini","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib11","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4599","article-title":"Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT)","volume":"28","author":"Bhargava","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/rp.59.1.51","article-title":"Functional significance of Tie2 signaling in the adult vasculature","volume":"59","author":"Peters","year":"2004","journal-title":"Recent Prog Horm Res"},{"key":"2022060800081626200_bib13","doi-asserted-by":"crossref","first-page":"9102","DOI":"10.1074\/jbc.275.13.9102","article-title":"Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt\/Survivin pathway","volume":"275","author":"Papapetropoulos","year":"2000","journal-title":"J Biol Chem"},{"key":"2022060800081626200_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"2022060800081626200_bib15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/path.1228","article-title":"Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia","volume":"198","author":"Currie","year":"2002","journal-title":"J Pathol"},{"key":"2022060800081626200_bib16","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4630","article-title":"Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC)","volume":"28","author":"Bullock","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib17","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1200\/JCO.2008.19.6683","article-title":"Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors","volume":"27","author":"Herbst","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.309","article-title":"AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study","volume":"29","author":"Rini","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib19","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2524","article-title":"First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2","volume":"28","author":"Rosen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib20","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01441414: PF-04856884 (CVX-060) in combination with axitinib in patients with previously treated metastatic renal cell carcinoma"},{"key":"2022060800081626200_bib21","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1\/2\u2013neutralizing peptibody","volume":"9","author":"Coxon","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022060800081626200_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"2022060800081626200_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdf213","article-title":"Phase II trial of thalidomide in renal-cell carcinoma","volume":"13","author":"Escudier","year":"2002","journal-title":"Ann Oncol"},{"key":"2022060800081626200_bib24","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.2003.01.536","article-title":"Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma","volume":"21","author":"Hernberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib25","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00005966: Interferon Alfa-2b with or without thalidomide in treating patients with metastatic or unresectable kidney cancer"},{"key":"2022060800081626200_bib26","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/cncr.22290","article-title":"Phase II study of lenalidomide in patients with metastatic renal cell carcinoma","volume":"107","author":"Choueiri","year":"2006","journal-title":"Cancer"},{"key":"2022060800081626200_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/COC.0b013e31815e451f","article-title":"Lenalidomide therapy for metastatic renal cell carcinoma","volume":"31","author":"Amato","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"2022060800081626200_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"2022060800081626200_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060800081626200_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"2022060800081626200_bib31","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01024231: A phase 1b, open-label, multicenter, multidose, dose-escalation study of BMS-936558 (MDX-1106) in combination with ipilimumab in subjects with unresectable stage III or stage IV malignant melanoma"},{"key":"2022060800081626200_bib32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.25639","article-title":"Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma","volume":"117","author":"Rini","year":"2011","journal-title":"Cancer"},{"key":"2022060800081626200_bib33","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.331","article-title":"A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106\/ONO-4538) in patients with RCC and other advanced refractory malignancies","volume":"29","author":"McDermott","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib35","article-title":"NCT01354431: A randomized, blinded, phase 2 dose-ranging study of BMS-936558 (MDX-1106) in subjects with progressive, advanced\/metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy"},{"key":"2022060800081626200_bib36","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4529","article-title":"Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC)","volume":"28","author":"Reinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib37","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2587","article-title":"Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC)","volume":"28","author":"Singh","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1179\/146532810X12858955921159","article-title":"Lactobacillus acidophilus and Bifidobacterium bifidum stored at ambient temperature are effective in the treatment of acute diarrhoea","volume":"30","author":"Rerksuppaphol","year":"2010","journal-title":"Ann Trop Paediatr"},{"key":"2022060800081626200_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060800081626200_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2008.192","article-title":"Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26\/CD80\/IL-2 in patients with metastatic renal cell carcinoma","volume":"21","author":"Buchner","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2022060800081626200_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e15067","article-title":"Preclinical efficacy data of MGN1601, a tumor vaccine comprising 4-fold gene-modified and irradiated allogeneic tumor cells in combination with a DNA-based immunomodulator for the treatment of metastatic renal carcinoma","volume":"28","author":"Volz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e15104","article-title":"Safety data of MGN1601, a tumor vaccine, made of allogeneic, transfected, and irradiated tumor cells in combination with an immunomodulator for the treatment of metastatic renal cell carcinoma","volume":"28","author":"Schmidt","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib43","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2000.18.12.2419","article-title":"Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer","volume":"18","author":"Rini","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib44","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6602209","article-title":"Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma","volume":"91","author":"Waters","year":"2004","journal-title":"Br J Cancer"},{"key":"2022060800081626200_bib45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cncr.20795","article-title":"A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma","volume":"103","author":"Rini","year":"2005","journal-title":"Cancer"},{"key":"2022060800081626200_bib46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1470-2045(09)70383-3","article-title":"Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)","volume":"11","author":"Bellmunt","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060800081626200_bib47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1442-2042.2009.02308.x","article-title":"Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma","volume":"16","author":"Soga","year":"2009","journal-title":"Int J Urol"},{"key":"2022060800081626200_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00280-007-0568-7","article-title":"A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma","volume":"61","author":"Amato","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022060800081626200_bib49","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5100","article-title":"A phase II study of S-1 for the treatment of cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Naito","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib50","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1200\/JCO.2011.37.5691","article-title":"Gastric cancer: Nagoya is not New York","volume":"29","author":"Macdonald","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib51","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roche","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib52","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","article-title":"Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes","volume":"25","author":"Denduluri","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib53","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2008.16.5019","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"26","author":"Thomas","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib54","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4161\/cbt.6.4.3831","article-title":"A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma","volume":"6","author":"Posadas","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"2022060800081626200_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"2022060800081626200_bib56","doi-asserted-by":"crossref","first-page":"16484","DOI":"10.1073\/pnas.0806574105","article-title":"Kinase requirements in human cells: III. Altered kinase requirements in VHL\u2212\/\u2212 cancer cells detected in a pilot synthetic lethal screen","volume":"105","author":"Bommi-Reddy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060800081626200_bib57","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-05-0617","article-title":"Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma","volume":"66","author":"Nakaigawa","year":"2006","journal-title":"Cancer Res"},{"key":"2022060800081626200_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.360","article-title":"C-met as a therapeutic target using ARQ 197 in renal cell carcinoma","volume":"29","author":"Gibney","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4516","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5008","article-title":"Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT)","volume":"29","author":"Buckanovich","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3522","article-title":"A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)","volume":"26","author":"Salgia","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","article-title":"Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib63","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.10502","article-title":"Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors","volume":"27","author":"Goldberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib64","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1038\/sj.onc.1202899","article-title":"Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists","volume":"18","author":"Michieli","year":"1999","journal-title":"Oncogene"},{"key":"2022060800081626200_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2152\/jmi.55.106","article-title":"Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor","volume":"55","author":"Tanimoto","year":"2008","journal-title":"J Med Invest"},{"key":"2022060800081626200_bib66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1535-7163.MCT-09-0824","article-title":"Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor","volume":"9","author":"Burgess","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022060800081626200_bib67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1464-410X.2010.09947.x","article-title":"A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma","volume":"108","author":"Sch\u00f6ffski","year":"2011","journal-title":"BJU Int"},{"key":"2022060800081626200_bib68","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors","volume":"16","author":"Gordon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060800081626200_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/neuonc\/noq198","article-title":"A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma","volume":"13","author":"Wen","year":"2011","journal-title":"Neuro Oncol"},{"key":"2022060800081626200_bib70","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1158\/1078-0432.CCR-09-2862","article-title":"A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors","volume":"16","author":"Rosen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060800081626200_bib71","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4621","article-title":"Fibroblast growth factor pathway in renal cell carcinoma","volume":"28","author":"Tsimafeyeu","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"2022060800081626200_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1684\/ecn.2009.0175","article-title":"Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist","volume":"20","author":"Alessi","year":"2009","journal-title":"Eur Cytokine Netw"},{"key":"2022060800081626200_bib74","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-07-1466","article-title":"A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"14","author":"Sarker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060800081626200_bib75","article-title":"A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer","volume":"29","author":"Andre","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.tps186","article-title":"A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3","volume":"29","author":"Milowsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.tps174","article-title":"A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer","volume":"29","author":"Tai","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib78","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01223027: An open-label, randomized, multi-center, phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. [cited 2011 Mar 19]."},{"key":"2022060800081626200_bib79","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01283945: An open-label, dose-escalation, phase I study to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of the dual VEGFR-FGFR tyrosine kinase inhibitor, E-3810, given orally as single agent to patients with advanced solid tumours"},{"key":"2022060800081626200_bib80","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01253668: Brivanib (BMS-582664, Brivanib Alaninate) in treatment of refractory metastatic renal cell carcinoma - a phase II pharmacodynamic and baseline biomarker study"},{"key":"2022060800081626200_bib81","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01202591: A randomised double-blind phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with exemestane vs exemestane alone in ER+ breast cancer patients with FGFR1 polysomy or gene amplification who have progressed following treatment with one prior endocrine therapy (adjuvant or first-line metastatic) (GLOW)"},{"key":"2022060800081626200_bib82","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1535-7163.MCT-09-0472","article-title":"The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases","volume":"9","author":"Bhide","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022060800081626200_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.327","article-title":"Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC)","volume":"29","author":"Bhargava","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib84","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib85","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"2022060800081626200_bib86","article-title":"A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC)","volume":"29","author":"Kabbinavar","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib87","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.4550","article-title":"Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC)","volume":"29","author":"Nosov","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib88","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00719264: A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney"},{"key":"2022060800081626200_bib89","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00631371: Phase 3b, randomized, open-label study of bevacizumab +temsirolimus) vs. bevacizumab + interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma. [cited 2010 Mar 29]."},{"key":"2022060800081626200_bib90","article-title":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00378703: The BeST Trial: a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST]"},{"key":"2022060800081626200_bib91","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1200\/JCO.2009.27.1759","article-title":"Toxicity of sunitinib plus bevacizumab in renal cell carcinoma","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib92","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.4516","article-title":"Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e15118","article-title":"Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): results from the French randomized phase II study TORAVA","volume":"29","author":"Escudier","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.315","article-title":"TORAVA trial: Lessons from this trial in the two control arms, sunitinib and bevacizumab in combination with interferon","volume":"29","author":"Escudier","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib95","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060800081626200_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3056","article-title":"Clinical pharmacokinetic-pharmacodynamic (PK\/PD) modeling study of the novel dual PI3K\/mTOR inhibitor BEZ235","volume":"29","author":"Bottino","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3066","article-title":"A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors","volume":"29","author":"Peyton","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib98","article-title":"NCT01283048: A phase I study of bevacizumab and escalation doses of BKM-120 in patients with metastatic renal cell carcinoma who failed prior systemic therapies. [cited 2011 Aug 29]."},{"key":"2022060800081626200_bib99","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.3003","article-title":"A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors","volume":"28","author":"Baselga","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3043","article-title":"Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy","volume":"29","author":"Grana","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib101","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5101","article-title":"A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI)","volume":"27","author":"Cho","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib102","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5034","article-title":"Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor","volume":"27","author":"Vogelzang","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib103","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800081626200_bib104","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1158\/1078-0432.CCR-07-1477","article-title":"Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma","volume":"13","author":"Ebbinghaus","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060800081626200_bib105","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/11\/3\/526\/2323161\/526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/11\/3\/526\/2323161\/526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:08:53Z","timestamp":1713571733000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/11\/3\/526\/91256\/Novel-Therapies-for-Metastatic-Renal-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,6]]},"published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-11-0806","relation":{},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}